title: Saphenous vein graft lesions: Are second-generation drug-eluting stents better?
abstract: Long-term outcomes were similar in patients treated with first- or second-generation drug-eluting stents (DES) for saphenous vein graft (SVG) lesions. Patients presenting with acute myocardial infarction as a result of occluded SVG may derive some benefit from the use of second- versus first-generation DES Randomized clinical trials are needed to determine whether newer DES types including those with bioabsorbable polymer or scaffolds offer a distinct advantage in the treatment of SVG lesions.
authors.affiliation: Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, Rhode Island.
authors.forename: Dhaval
authors.initials: D
authors.lastname: Kolte
authors.affiliation: Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, Rhode Island.
authors.forename: J
authors.initials: J
authors.lastname: Dawn Abbott
mesh_terms: D054855:Drug-Eluting Stents; D005544:Forecasting; D006083:Graft Occlusion, Vascular / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000601:surgery*; D062645:Percutaneous Coronary Intervention; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D012501:Saphenous Vein / Q000637:transplantation*; D014481:United States / Q000453:epidemiology